Welcome to our dedicated page for CytoMed Therapeutics SEC filings (Ticker: GDTC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles U.S. SEC filings for CytoMed Therapeutics Limited (NASDAQ: GDTC), a Singapore-based clinical stage biopharmaceutical company focused on donor-derived allogeneic cell-based immunotherapies for cancers. As a foreign private issuer, CytoMed reports primarily on Form 6-K, along with other applicable forms, to disclose material information to investors.
In these filings, readers can find press releases furnished as exhibits that detail clinical milestones, such as progress in the ANGELICA Phase I CAR gamma delta T cell trial in Singapore, memoranda of understanding for first-in-human γδ T cell trials in Malaysia, and collaborative research publications with The University of Texas MD Anderson Cancer Center on donor-derived Vγ9Vδ2 T cells for acute myeloid leukemia. Filings also cover interim and annual financial statements, management’s discussion and analysis of financial condition and results of operations, and information on at-the-market equity programs.
CytoMed’s SEC reports additionally describe corporate and strategic actions, including the acquisition of synergistic T cell technology assets, the purchase of a licensed cord blood bank in Malaysia, the creation of its cord blood-derived biotech platform under subsidiary LongevityBank, and changes in executive shareholdings. These documents offer insight into how the company funds and structures its gamma delta T cell, iPSC-derived hybrid cell, and cord blood-derived initiatives.
On Stock Titan, investors can access CytoMed’s latest SEC submissions as they are made available from EDGAR and use AI-powered summaries to interpret lengthy exhibits and financial sections. This helps clarify the implications of each 6-K, financial update, or transaction-related disclosure for GDTC’s clinical programs, regional expansion and capital strategy.
CytoMed Therapeutics Ltd (GDTC) filed a Form 144 notifying a proposed sale of 54,644 ordinary shares with an aggregate market value of $102,731 to be sold approximately on 09/23/2025 on NASDAQ. The filer reports total outstanding shares of 11,733,712. The securities were originally acquired by share subscription on 04/22/2021 (payment noted as cash on 04/20/2021) totaling 711,822 shares at acquisition. The filing also lists prior open-market sales by the same account during Aug–Sep 2025 totaling 26,838 shares sold over multiple dates, with individual gross proceeds reported per sale. The notice includes the required representation that the seller is not aware of undisclosed material adverse information.
CytoMed Therapeutics Limited reported that it has successfully expanded clinical-scale natural killer (NK) cells from cord blood units, adding to its existing adult peripheral blood mononuclear cell-derived therapeutics. The company intends to reorganize and streamline its group structure to create a new cord blood-derived biotech business. According to the referenced press release, this move supports an expansion into auto-immune diseases and builds on a recent cord blood bank acquisition.
CytoMed Therapeutics Limited (GDTC) prospectus supplement (Form 424B5) provides table-of-contents items and partial financial and capitalization data related to an offering and pro forma adjustments. The filing shows ordinary shares outstanding of 11,540,000 on an actual basis, 11,836,348 pro forma and 14,268,520 as adjusted (assuming 2,432,172 shares issued in the offering). Total liabilities are presented as 1,023,960 and 749,495 (two comparative figures). Accumulated losses are shown as (14,848,135) and (10,868,200) with pro forma accumulated losses of (16,224,695) and (11,875,783). Total capitalization appears as 10,067,749 and 7,369,162 with an as-adjusted capitalization of 15,587,229 and 11,409,185. Net tangible assets are reported as 8,950,739 and 6,551,558 and as-adjusted 14,470,219 and 10,591,581, with net tangible asset per share figures around $0.78, $0.57, and as-adjusted $1.01/$0.74. The supplement also includes Malaysian tax rate references (examples: 17%, 24%, royalties 10%, interest 15%, dividends exempt). Much of the provided text is a table of contents and fragmented table rows rather than full narrative disclosure.
CytoMed Therapeutics (GDTC) filed a Form 6-K to furnish a 21 Jul 2025 press release. The company has completed Dose Level 1 of its first-in-human Phase I dose-escalation “ANGELICA” trial of CTM-N2D, an investigational cell therapy for patients with advanced solid tumours or haematological malignancies, and has been cleared to begin Dose Level 2. The milestone indicates initial safety/tolerability at the starting dose, a prerequisite for further escalation and eventual efficacy assessment.
The filing contains no financial data, guidance, or corporate transactions; its sole purpose is to publicly disclose this clinical progress (Exhibit 99.1). Investors should view the news as an early-stage, non-pivotal signal of programme momentum rather than a determinant of near-term revenue.
CytoMed Therapeutics has received Notice of Effectiveness from the SEC for its Form F-3 registration statement (File No. 333-288033), effective as of June 23, 2025, at 4:00 P.M.
Form F-3 is a securities registration statement used by foreign companies that are already listed on a U.S. exchange and meet certain eligibility requirements. This effectiveness notice indicates that CytoMed can now proceed with its planned securities offering as outlined in the registration statement.
The effectiveness of this F-3 filing suggests that CytoMed may be planning to:
- Raise additional capital through securities offerings
- Register securities for potential future offerings
- Enhance its financial flexibility for future growth initiatives
CytoMed Therapeutics Limited (NASDAQ: GDTC) has filed a Form 144 indicating the proposed sale of 81,482 ordinary shares, valued at roughly $171,112 based on the market price disclosed in the filing. The seller—whose name is not provided in the excerpt—plans to execute the transaction through Bank of Singapore on or about 23 June 2025. The company has 11.54 million shares outstanding, so the notice represents approximately 0.7 % of total shares.
The securities were originally acquired via a share subscription on 22 April 2021. The filing also discloses that the same holder has sold 4,928 shares over the past three months, generating aggregate gross proceeds of $11,548.72. No adverse, non-public information is claimed to be known by the seller, as required under Rule 144 representations.
While Form 144 filings do not guarantee that a sale will occur, they signal the intent of an affiliate or insider to liquidate shares. Investors often monitor such filings as a gauge of insider sentiment and potential stock-supply overhang. The transaction size is modest relative to the public float, but it may still weigh on short-term sentiment given GDTC’s limited trading volume as a small-cap biotech.